Glaxo Wellcome has decided not to take up its option to negotiate a licensing agreement for the oral form of British Biotech's antiasthma drug lexipafant. The oral compound, also being evaluated by BB in intravenous form for the treatment of acute pancreatitis, has been in Phase II trials, the results of which, GW has concluded, showed no significant improvement in respiratory function compared to placebo.
The news came from BB through its interim results for the three months to July 31 (which will be reported in the Marketletter next week). GW is making no statement other than to confirm its decision not to continue with this project. BB also said it expects to announce interim results in November of its Phase III trials with lexipafant in pancreatitis, and if these confirm the positive data of Phase II studies, it will submit a European Marketing Authorization Application by the end of the first quarter of 1997.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze